{"transactions":[{"id":699860,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-31T20:45:07.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":23370,"price":14.72,"value":344006.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $14.80, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1."}],"balance_after":64745,"source":{"system":"sec-edgar","filing":"0001140361-26-030514","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126030514/form4.xml","form_type":"4"}},{"id":703432,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2026-07-24T22:10:54.000Z","date":"2026-07-22","kind":"exercise","planned":false,"acquired":false,"shares":20052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20052},"source":{"system":"sec-edgar","filing":"0001140361-26-029635","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029635/form4.xml","form_type":"4"}},{"id":703431,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-24T22:10:54.000Z","date":"2026-07-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":1671,"price":13.82,"value":23093.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023."}],"balance_after":88115,"source":{"system":"sec-edgar","filing":"0001140361-26-029635","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029635/form4.xml","form_type":"4"}},{"id":703430,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-24T22:10:54.000Z","date":"2026-07-22","kind":"exercise","planned":false,"acquired":true,"shares":5694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of 5,694 shares of Common Stock (\"Common Stock\") of AngioDynamics, Inc. (\"AngioDynamics\") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023."}],"balance_after":89786,"source":{"system":"sec-edgar","filing":"0001140361-26-029635","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029635/form4.xml","form_type":"4"}},{"id":704634,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2026-07-23T00:06:04.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":17966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."}],"balance_after":17966,"derivative":{"underlying":"Common Stock","underlying_shares":17966},"source":{"system":"sec-edgar","filing":"0001140361-26-029332","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029332/form4.xml","form_type":"4"}},{"id":704633,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-23T00:06:04.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":17966,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition of 17,966 shares of common stock (\"Common Stock\") of AngioDynamics, Inc. represents 17,966 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030."}],"balance_after":84092,"source":{"system":"sec-edgar","filing":"0001140361-26-029332","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029332/form4.xml","form_type":"4"}},{"id":705127,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-22T00:21:29.000Z","date":"2026-07-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":251,"price":13.71,"value":3441.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The exempt disposition of 251 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022."}],"balance_after":66126,"source":{"system":"sec-edgar","filing":"0001140361-26-029181","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029181/form4.xml","form_type":"4"}},{"id":705126,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-22T00:21:29.000Z","date":"2026-07-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1373,"price":13.51,"value":18549.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 1,373 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024."}],"balance_after":66377,"source":{"system":"sec-edgar","filing":"0001140361-26-029181","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029181/form4.xml","form_type":"4"}},{"id":705125,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2026-07-22T00:21:29.000Z","date":"2026-07-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2153,"price":14.14,"value":30443.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exempt disposition of 2,153 shares of common stock of AngioDynamics, Inc. (\"AngioDynamics\") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025."}],"balance_after":67750,"source":{"system":"sec-edgar","filing":"0001140361-26-029181","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126029181/form4.xml","form_type":"4"}},{"id":1083293,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2025-07-22T22:22:20.000Z","date":"2025-07-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":277,"price":8.99,"value":2490.23,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The exempt disposition of 277 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021."}],"balance_after":69903,"source":{"system":"sec-edgar","filing":"0001140361-25-026798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125026798/form4.xml","form_type":"4"}},{"id":1083292,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2025-07-22T22:22:20.000Z","date":"2025-07-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":251,"price":8.69,"value":2181.19,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 251 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022."}],"balance_after":70180,"source":{"system":"sec-edgar","filing":"0001140361-25-026798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125026798/form4.xml","form_type":"4"}},{"id":1083291,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2025-07-22T22:22:20.000Z","date":"2025-07-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":735,"price":8.69,"value":6387.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exempt disposition of 735 shares of common stock of AngioDynamics, Inc. (\"AngioDynamics\") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023."}],"balance_after":70431,"source":{"system":"sec-edgar","filing":"0001140361-25-026798","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125026798/form4.xml","form_type":"4"}},{"id":1084585,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2025-07-18T22:06:29.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":29349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."}],"balance_after":29349,"derivative":{"underlying":"Common Stock","underlying_shares":29349},"source":{"system":"sec-edgar","filing":"0001140361-25-026465","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125026465/form4.xml","form_type":"4"}},{"id":1084584,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2025-07-18T22:06:29.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":29349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition of 29,349 shares of common stock (\"Common Stock\") of AngioDynamics, Inc. represents 29,349 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029."}],"balance_after":71166,"source":{"system":"sec-edgar","filing":"0001140361-25-026465","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125026465/form4.xml","form_type":"4"}},{"id":1299831,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2025-01-17T21:05:54.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":4060,"price":12.31,"value":49978.6,"ownership":{"direct":true},"balance_after":41817,"source":{"system":"sec-edgar","filing":"0001140361-25-001388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036125001388/form4.xml","form_type":"4"}},{"id":1388041,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-10-10T19:22:57.000Z","date":"2024-10-10","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":6.08,"value":608.0,"ownership":{"direct":true},"balance_after":45877,"source":{"system":"sec-edgar","filing":"0001140361-24-043263","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124043263/form4.xml","form_type":"4"}},{"id":1388040,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-10-10T19:22:57.000Z","date":"2024-10-07","kind":"purchase","planned":false,"acquired":true,"shares":768,"price":6.09,"value":4677.12,"ownership":{"direct":true},"balance_after":45777,"source":{"system":"sec-edgar","filing":"0001140361-24-043263","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124043263/form4.xml","form_type":"4"}},{"id":1442664,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2024-08-03T01:50:55.000Z","date":"2024-07-17","kind":"exercise","planned":false,"acquired":true,"shares":7550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7550},"source":{"system":"sec-edgar","filing":"0001140361-24-035599","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124035599/form4.xml","form_type":"4"}},{"id":1442663,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-08-03T01:50:55.000Z","date":"2024-07-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1666,"price":7.4,"value":12328.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 1,666 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021."}],"balance_after":45009,"source":{"system":"sec-edgar","filing":"0001140361-24-035599","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124035599/form4.xml","form_type":"4"}},{"id":1442662,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-08-03T01:50:55.000Z","date":"2024-07-17","kind":"exercise","planned":false,"acquired":true,"shares":5677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of 5,677 shares of Common Stock (\"Common Stock\") of AngioDynamics, Inc. (\"AngioDynamics\") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021."}],"balance_after":46675,"source":{"system":"sec-edgar","filing":"0001140361-24-035599","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124035599/form4.xml","form_type":"4"}},{"id":1448619,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-07-26T01:00:17.000Z","date":"2024-07-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":277,"price":7.13,"value":1975.01,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 277 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 21, 2021."}],"balance_after":40998,"source":{"system":"sec-edgar","filing":"0001140361-24-034269","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124034269/form4.xml","form_type":"4"}},{"id":1448618,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-07-26T01:00:17.000Z","date":"2024-07-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":251,"price":7.13,"value":1789.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exempt disposition of 251 shares of common stock of AngioDynamics, Inc. (\"AngioDynamics\") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022."}],"balance_after":41275,"source":{"system":"sec-edgar","filing":"0001140361-24-034269","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124034269/form4.xml","form_type":"4"}},{"id":1449853,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-07-23T10:01:30.000Z","date":"2024-07-19","kind":"tax_withholding","planned":false,"acquired":false,"shares":735,"price":7.18,"value":5277.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The exempt disposition of 735 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023."}],"balance_after":41526,"source":{"system":"sec-edgar","filing":"0001140361-24-033785","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033785/form4.xml","form_type":"4"}},{"id":1451114,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-07-19T21:18:35.000Z","date":"2024-07-17","kind":"grant","planned":false,"acquired":true,"shares":23507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028."}],"balance_after":23507,"derivative":{"exercise_price":7.4,"exercise_date":"2025-07-17","expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":23507},"source":{"system":"sec-edgar","filing":"0001140361-24-033634","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033634/form4.xml","form_type":"4"}},{"id":1451113,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2024-07-19T21:18:35.000Z","date":"2024-07-17","kind":"grant","planned":false,"acquired":true,"shares":23952,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."}],"balance_after":23952,"derivative":{"underlying":"Common Stock","underlying_shares":23952},"source":{"system":"sec-edgar","filing":"0001140361-24-033634","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033634/form4.xml","form_type":"4"}},{"id":1451112,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"officer":true,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2024-07-19T21:18:35.000Z","date":"2024-07-17","kind":"grant","planned":false,"acquired":true,"shares":18733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition of 18,733 shares of common stock (\"Common Stock\") of AngioDynamics, Inc. represents 18,733 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028."}],"balance_after":42261,"source":{"system":"sec-edgar","filing":"0001140361-24-033634","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124033634/form4.xml","form_type":"4"}},{"id":2203181,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2022-07-22T22:42:14.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":8027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026."}],"balance_after":8027,"derivative":{"exercise_price":21.53,"exercise_date":"2023-07-20","expiration_date":"2032-07-20","underlying":"Common Stock","underlying_shares":8027},"source":{"system":"sec-edgar","filing":"0001567619-22-014375","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922014375/doc1.xml","form_type":"4"}},{"id":2203180,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2022-07-22T22:42:14.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":6852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited."}],"balance_after":6852,"derivative":{"underlying":"Common Stock","underlying_shares":6852},"source":{"system":"sec-edgar","filing":"0001567619-22-014375","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922014375/doc1.xml","form_type":"4"}},{"id":2203179,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2022-07-22T22:42:14.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":3426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The acquisition of 3,426 shares of common stock (\"Common Stock\") of AngioDynamics, Inc. represents 3,426 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026."}],"balance_after":39619,"source":{"system":"sec-edgar","filing":"0001567619-22-014375","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922014375/doc1.xml","form_type":"4"}},{"id":2209130,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Performance Right","published_at":"2022-07-11T10:15:28.000Z","date":"2022-07-07","kind":"exercise","acquired":false,"shares":6452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6452},"source":{"system":"sec-edgar","filing":"0001567619-22-013846","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922013846/doc1.xml","form_type":"4"}},{"id":2209129,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2022-07-11T10:15:28.000Z","date":"2022-07-07","kind":"tax_withholding","acquired":false,"shares":919,"price":20.54,"value":18876.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The exempt disposition of 919 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019."}],"balance_after":36193,"source":{"system":"sec-edgar","filing":"0001567619-22-013846","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922013846/doc1.xml","form_type":"4"}},{"id":2209128,"issuer":{"id":5275,"kind":"organization","name":"ANGIODYNAMICS INC"},"owners":[{"id":27470,"kind":"person","name":"Nighan Warren JR","position":1,"cik":"0001507345","reported_name":"Nighan Warren JR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Quality and Regulatory"}}],"security":"Common Stock","published_at":"2022-07-11T10:15:28.000Z","date":"2022-07-07","kind":"exercise","acquired":true,"shares":3233,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of 3,233 shares of common stock (\"Common Stock\") of AngioDynamics, Inc. (the \"Company\") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019."}],"balance_after":37112,"source":{"system":"sec-edgar","filing":"0001567619-22-013846","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1275187/000156761922013846/doc1.xml","form_type":"4"}}]}